GSK Advances Toward Functional Cure for Chronic Hepatitis B

Key Developments

• GSK’s bepirovirsen met the main goal in two Phase 3 trials aimed at achieving a functional cure for chronic hepatitis B infection.
• The therapy is an antisense oligonucleotide that could serve as an alternative to current antiviral drugs requiring lifelong administration.

Implications

• This advancement addresses a critical unmet need for hepatitis B patients seeking a finite treatment.
• A functional cure could significantly reduce the long-term burden of chronic hepatitis B globally.

Outlook

• Pending regulatory review, bepirovirsen could usher in a new treatment paradigm for hepatitis B.
• Further real-world data will be essential to confirm durability and safety of the functional cure.

Source: MedCity News